• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Moderna, Inc. - Common Stock (NQ:MRNA)

    231.56 +10.73 (+4.86%)
    Delayed Quote Updated: 1:42 PM EST, Nov 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Moderna, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗
    Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside. 
    Via MarketBeat
    Topics Artificial Intelligence Earnings Initial Public Offering
    News headline image
    Could Investing in Moderna's Stock Double Your Money? ↗
    The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future. 
    Via The Motley Fool
    News headline image
    If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started ↗
    Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma. 
    Via The Motley Fool
    News headline image
    Stock Split Watch: Is Moderna Next? ↗
    Moderna stock has skyrocketed this year. 
    Via The Motley Fool
    News headline image
    These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away ↗
    These biotechs’ valuations are through the roof. 
    Via The Motley Fool
    News headline image
    Will Moderna Soar on Nov. 6? ↗
    Moderna shares have outperformed tech giants this year. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility ↗
    Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size. 
    Via The Motley Fool
    News headline image
    Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗
    Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved. 
    Via MarketBeat
    S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fall ↗
    Via Chartmill
    Topics Stocks
    S&P 500 Gap-Down Stocks for Oct. 26, 2026 ↗
    Via Chartmill
    Topics Stocks
    S&P 500 Premarket Movers: Gainers and Losers Before the Open ↗
    Via Chartmill
    Topics Stocks
    News headline image
    A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
    News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
    EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial ↗
    Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The... 
    Via MarketBeat
    Topics Artificial Intelligence
    Most Active S&P 500 Stocks for Oct. 23, 2026 ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? ↗
    The stock fell 17% in one trading session. 
    Via The Motley Fool
    News headline image
    Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline
    From Law Offices of Howard G. Smith
    Via Business Wire
    S&P 500 Premarket Movers: CCI and SBAC Lead Gainers, TYL and DECK Top Decliners ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Moderna Named a Top Employer by Science for Twelfth Consecutive Year
    From Moderna, Inc.
    Via ACCESS Newswire
    News headline image
    Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports ↗
    Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    Why Moderna (MRNA) stock is trading lower today
    What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per... 
    Via StockStory
    Topics Government
    News headline image
    Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 23.07% Stock Decline
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    S&P 500 Top Movers: Gainers and Losers for Oct. 22, 2026 ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
    From Merck & Co., Inc.
    Via Business Wire
    Most Active S&P 500 Stocks on Oct. 22: Netflix, Super Micro, Moderna ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗
    The market has rewarded this biotech for its breakthroughs. 
    Via The Motley Fool
    News headline image
    Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗
    This company made headlines with its coronavirus vaccine. 
    Via The Motley Fool
    News headline image
    2 Large-Cap Stocks to Research Further and 1 That Underwhelm
    Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
    Via StockStory
    S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall ↗
    Via Chartmill
    Topics Stocks
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.